Quantcast

Latest placebo Stories

2014-08-25 08:27:22

ENGLEWOOD, Colo., Aug. 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is issuing this response to the most commonly asked questions in regards to the STEP study and clarify its plan for moving forward with Ampion(TM) for osteoarthritis of the knee. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Letter to Ampio Shareholders from Michael Macaluso, Chairman & CEO and David Bar-Or, MD, Chief Scientific Officer The STEP study of Ampion(TM)...

2014-08-21 20:22:34

LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced positive, statistically significant results from a randomized, double-blind Phase 2a study of CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The results...

2014-08-21 08:28:33

ENGLEWOOD, Colo., Aug. 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a delay in the data analysis of the STEP Study due to the discovery by the independent Clinical Research Organization (CRO) that the study drug (both Ampion(TM) and the placebo) were, during shipment to the clinical sites, exposed to lower temperatures than permitted by the drug specifications. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Michael Macaluso, Ampio's...

2014-08-21 08:28:27

Mid and High Level Doses Demonstrate Statistically Significant Improvement in Cellulite Across All Endpoints; Nearly 70% of Mid and High Dose Patients Satisfied or Very Satisfied with Results CHESTERBROOK, Pa., Aug. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous...

2014-08-14 23:01:06

New Onnit T+ Formula Increases Strength 36% Over Placebo In FSU Clinical Trial AUSTIN, TX (PRWEB) August 14, 2014 A groundbreaking clinical trial for strength based athletes has just been presented at this year’s National Strength and Conditioning Association (NSCA) annual conference. Dr. Michael Ormsbee, a professor of human sciences at Florida State University, led a team of investigators to analyze a 4-week supplementation regimen of Onnit’s T+ on college-aged powerlifters. T+ is...

2014-08-05 23:06:47

JDS Therapeutics Announces U.S. Launch of Physician Recommended Relizen®, a Safe, Natural Therapy for Hot Flashes Los Angeles (PRWEB) August 05, 2014 Relizen®†, a patented, non-hormonal nutritional supplement for the relief of hot flashes associated with menopause, is now available to U.S. consumers for purchase at Relizen.com. Over 43 million women are of menopausal age in the United States. Seventy-five percent of women report experiencing hot flashes, and 87 percent of...

2014-07-29 08:33:38

NEW YORK, July 29, 2014 /PRNewswire/ -- Recently unveiled at the annual American Society of Clinical Psychopharmacology conference in Hollywood, FL, a new randomized, double-blinded, placebo-controlled human clinical trial conducted by The Brain Institute, at the University of Utah, found that adolescent males experienced increased motor speed and attention after supplementation of citicoline. The trial involved 75 adolescent males over a 28-day period in which the citicoline, a known...

2014-07-25 10:45:39

The Lancet Paracetamol is no better than placebo at speeding recovery from acute episodes of lower back pain or improving pain levels, function, sleep, or quality of life, according to the first large randomised trial to compare the effectiveness of paracetamol with placebo for low-back pain. The findings, published in The Lancet, question the universal endorsement of paracetamol as the first choice painkiller for low-back pain, say the authors. Low-back pain is the leading cause of...

2014-07-21 10:19:04

North Shore-Long Island Jewish (LIJ) Health System The brain network measures placebo effects in Parkinson's disease patients Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. Parkinson's disease is the second most common neurodegenerative disease in the...

2014-07-17 16:26:33

MELBOURNE, Australia, July 17, 2014 /PRNewswire/ -- Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) has today provided an update on its clinical development program for Alzheimer's disease. Professor Colin Masters, the Florey Institute of Neuroscience and Mental Health, The University of Melbourne, will today include data from Prana's Phase 2 IMAGINE and EURO trials in his presentation at the Alzheimer's Association International Conference in Copenhagen, Denmark. The presentation is...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related